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Edited by Masayuki MiyasakaAbstract In the present study, we characterized regions of hu-
man heat shock protein (HSP) 60 responsible for binding to pri-
mary macrophages. Studies using 20-mer peptides of the HSP60
sequence to compete with HSP60-binding to macrophages from
C57BL/6J mice showed that regions aa241–260, aa391–410 and
aa461–480 are involved in surface-binding. HSP60 mutants,
lacking the N-terminal 137, 243 or 359 amino acids, inhibited
HSP60-binding to primary macrophages to diﬀerent degrees,
demonstrating that all three regions are required for optimal
binding. Analysis of diﬀerent pro- and eukaryotic HSP60 species
indicated that phylogenetically separate HSP60 species use dif-
ferent binding sites on primary macrophages.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Macrophages1. Introduction
Heat shock proteins (HSPs) are ubiquitously expressed,
highly conserved proteins, known to act as molecular chaper-
ones with important functions in the synthesis and degradation
of proteins [1,2]. HSP60, one prominent member of this pro-
tein family, has been identiﬁed as immunodominant target of
autoantibodies and autoimmune T-cells in healthy individuals
as well as in patients suﬀering from inﬂammatory diseases like
arthritis, type 1 diabetes and atherosclerosis [3–6]. In addition,
HSP60 has been suggested to induce regulatory T-cell re-
sponses via the interaction with the innate immune system
[7]. We and others have shown that HSP60 induces the release
of pro-inﬂammatory mediators (tumor necrosis factor a, nitric
oxide, interleukin (IL)-6) by cells of the innate immune system
such as macrophages and dendritic cells [8–11]. Furthermore,Abbreviations:HSP, heat shock protein; IL, interleukin; TLR, Toll-like
receptor; BMM, bone marrow-derived macrophages
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helper 1 promoting cytokines IL-12 and IL-15 in those cells [8].
In an initial approach to characterize the receptor structure
for HSP60 on macrophages, we could demonstrate that
HSP60-binding to macrophages is independent of Toll-like
receptor (TLR)4 [12], whereas the inﬂammatory signaling of
HSP60 requires the presence of a functionally active TLR4
[10,11,13,14]. The C-terminal region aa481–500 of the HSP60
molecule has been identiﬁed as being responsible for binding
to the surface of the macrophage line J774A.1 [15].
Recently, we identiﬁed a speciﬁc binding site for LPS on the
human HSP60 molecule, region aa354–365, which is suggested
to be involved in macrophage activation [16]. These ﬁndings
indicate that the interaction of HSP60 and innate immune cells
represents a highly complex process including the contact of
HSP60 with cell surface structures involved in binding and
in the initiation of a pro-inﬂammatory response. Further elu-
cidation of the primary interactions of HSP60 with innate im-
mune cells will improve our understanding of the
immunomodulatory role of HSP60 on adaptive immune cells
and on the development of numerous organ-speciﬁc disease
processes. Therefore, the present study was designed to char-
acterize the HSP60 epitope(s) responsible for binding to pri-
mary bone marrow-derived macrophage (BMM) from
C57BL/6J mice. We identiﬁed three amino acid regions of
the HSP60 molecule as being involved in the interaction with
surface structures on primary macrophages, aa241–260,
aa391–410 and aa461–480.2. Materials and methods
2.1. Cell lines and mice
The mouse macrophage cell line J774A.1 was purchased from the
German Collection of Microorganisms and Cell Culture (Braun-
schweig, Germany) and was cultured as previously described [8].
C57BL/6J mice (8–12 weeks old) were purchased from the Jackson
Laboratories (Bar Harbor, ME). Bone marrow cells were obtained
by ﬂushing femurs and tibias with ice-cold PBS and washed by centri-
fugation (500 · g, 10 min). A total of 3.5 · 106 bone marrow cells were
incubated in tissue culture dishes in 10 ml Pluznik medium containing
5% horse serum, 15% FBS, 15% L929 cell-conditioned medium and
65% RPMI 1640 supplemented with 2 mM glutamine [13]. After 3 days
of culture 50% of the cells were characterized as CD11b+ macrophages
and were used for further studies.blished by Elsevier B.V. All rights reserved.
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Recombinant human HSP60 was obtained from Peptor Ltd. (Reho-
vot, Israel) or Loke Diagnostics ApS (Aarhus, Denmark). Recombi-
nant Chlamydia pneumoniae HSP60 was kindly provided by Dr. T.
Miethke (Institute for Medical Microbiology, Immunology and Hy-
giene, Technical University of Munich, Munich, Germany). Recombi-
nant mouse HSP60 and Mycobacterium bovis HSP65 were obtained
from the Department of Infectious Diseases and Immunology, Faculty
of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.
Recombinant rat HSP60 and Escherichia coli GroEL were purchased
from StressGen Biotechnologies (Victoria BC, Canada). Recombinant
hamster HSP60 was obtained from IMMPACT Biotechnologies
GmbH (Hamburg, Germany). A complete set of overlapping peptides
of 20aa, spanning the sequence of the unprocessed precursor of human
HSP60 (Swiss-Prot. P10809) from aa1–560, was from the Department
of Immunohematology and Blood Transfusion (Leiden University
Medical Center, Leiden, The Netherlands) [17]. Mutants of human
HSP60, N-terminally deleted and covering the human HSP60 sequence
from aa138–573, aa244–573 or aa360–573 were prepared as previously
described [16].
2.3. Generation of recombinant Histoplasma capsulatum HSP60 and
HSP60 fragment 1–4
Recombinant H. capsulatum HSP60 corresponding to the sequence
of the unprocessed precursor of H. capsulatum HSP60 (Swiss-Prot.
P50142) from aa40–590 [18] and recombinant H. capsulatum HSP60-
derived fragment 1 (aa40–328), fragment 2 (aa131–394), fragment 3
(aa214–484) and fragment 4 (aa373–590) have been synthesized as pre-
viously described [19,20].
2.4. HSP60-binding and -inhibition studies
Labeling of human HSP60 with ﬂuorescence dye using the Alexa
Fluor488 Protein Labeling kit (Molecular Probes, Leiden, The
Netherlands) and HSP60-binding and -inhibition studies were per-
formed as described previously [12]. Brieﬂy, BMMs from C57BL/6J
mice or J774A.1 cells (1 · 106 cells/ml) were incubated in a total vol-
ume of 100 ll in the presence of human HSP60-Alexa488 for 45 min
on ice for the binding studies. Subsequently, cells were washed with
PBS/1% BSA and resuspended in PBS containing 1% paraformalde-
hyde. For the inhibition studies the macrophages were preincubated
with unlabeled HSP60, the diﬀerent peptides, HSP60 mutants or
HSP60 species at the indicated concentrations for 30 min at 4 C. Then
HSP60-Alexa488 was added and the incubation was continued for an-
other 45 min on ice. After washing and ﬁxation steps, the samples were
evaluated using a FACSCalibur ﬂow cytometer (BD Bioscience, Rock-
ville, CA). Cell surface-binding of HSP60-Alexa488 was calculated
using the geometric mean ﬂuorescence value of the cells. Inhibition
was deﬁned as the reduction of the geometric mean ﬂuorescence value
of HSP60-Alexa488-binding to the cells.
2.5. Statistical analysis
Data were expressed as mean values + S.D. Statistical analysis was
performed using the Student t test. Diﬀerences were considered statis-
tically signiﬁcant with P < 0.05. Sequence analysis was performed
using Swiss-Prot analysis tools (www.expasy.org).pep241-260
pep391-410
pep461-480
pep481-500
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Fig. 1. Eﬀect of 20-mer peptides on HSP60-binding to macrophages.
(A) BMM from C57BL/6J mice were preincubated with diﬀerent 20-
mer peptides of the human HSP60 sequence (125 lM, 30 min).
Subsequently, 500 nM HSP60-Alexa488 was added and the incubation
was continued for another 45 min on ice. (B) J774A.1 macrophages
were preincubated with selected 20-mer peptides (125 lM, 30 min),
followed by the addition of 350 nM HSP60-Alexa488 and further
incubation for 45 min on ice. The analysis was performed by ﬂow
cytometry. Inhibition of HSP60-Alexa488-binding is indicated as %.3. Results
3.1. Identiﬁcation of HSP60-binding epitopes by inhibition
studies with HSP60 peptides
In order to identify epitope(s) of the human HSP60 molecule
involved in binding to primary macrophages we analyzed the
eﬀect of a complete set of overlapping 20-mer peptides, cover-
ing the human HSP60 sequence from aa1–560, on the binding
of HSP60 to BMM from C57BL/6J mice. In these experiments
peptides were screened at a concentration of 125 lM for inhib-
iting binding of ﬂuorescence-labeled human HSP60 (HSP60-
Alexa488). Three peptides corresponding to aa241–260
(pep241–260), aa391–410 (pep391–410) and aa461–480(pep461–480) were found to induce strong inhibition of
HSP60-Alexa488-binding, i.e., around 50% (Fig. 1A). Since
this ﬁnding was in strong contrast to our previous observation
that the region aa481–500 of HSP60 is involved in binding to
the macrophage line J774A.1, we again analyzed the eﬀect of
these peptides on HSP60-Alexa488-binding to J774A.1 macro-
phages (Fig. 1B). As expected, pep481–500 competed with
HSP60 for binding to these cells (75% inhibition). By contrast,
none of the three peptides pep241–260, pep391–410 and
pep461–480 inhibited HSP60-binding. In a more detailed anal-
ysis, we tested pep241–260, pep391–410 and pep461–480, the
appropriate adjacent peptides and pep481–500 on HSP60-
binding to primary macrophages at the concentrations of 5
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Fig. 3. Eﬀect of selected HSP60 mutants on HSP60-binding to
macrophages. BMM from C57BL/6J mice were incubated in the
absence (autoﬂuorescence) or presence of 500 nM HSP60-Alexa488
(HSP60\) for 45 min on ice. For inhibition studies cells were
preincubated (30 min) with 5 lM unlabeled HSP60 or 5 lM of the
unlabeled HSP60 deletion mutants (aa138–573, aa244–573 or aa360–
573), followed by incubation with HSP60\. The analysis was per-
formed by ﬂow cytometry and binding of HSP60\ alone was set 100%.
C. Habich et al. / FEBS Letters 580 (2006) 115–120 117and 125 lM. Pep241–260 and pep461–480 led to a signiﬁcant
(P < 0.05) reduction of HSP60-Alexa488-binding to BMM
from C57BL/6J mice to 52% and 40%, respectively (Fig. 2).
Pep391–410 was also signiﬁcantly (P < 0.05) inhibitory when
used at a concentration of 125 lM and reduced HSP60-
Alexa488-binding to primary macrophages to 43%. None of
the peptides adjacent to pep241–260, pep391–410 or pep461–
480 inhibited HSP60-Alexa488-binding, nor did pep481–500.
3.2. Mapping of HSP60-binding epitopes by HSP60 mutants
Subsequently, we analyzed three diﬀerent N-terminally de-
leted mutants of human HSP60, which have been found to
compete with HSP60-binding to J774A.1 macrophages in a
similar degree as the full-length HSP60 molecule [15]. Three
HSP60 mutants, comprising the C-terminal regions aa138–
573, aa244–573 or aa360–573 were tested for the inhibition
of binding of HSP60-Alexa488 to BMM from C57BL/6J
mice. At a concentration of 5 lM all three mutants reduced
HSP60-binding to high, but diﬀerent degrees (Fig. 3).
HSP60 mutant aa138–573, which includes the regions of the
three inhibitory 20-mer peptides pep241–260, pep391–410
and pep461–480, showed the strongest inhibitory eﬀect on
HSP60-binding, i.e., 93% inhibition. HSP60 mutant aa244–
573, comprising the amino acid region of pep391–410,
pep461–480 and of pep241–260 with the exception of the
three N-terminal amino acids, had an inhibitory eﬀect of
80%. Finally, HSP60 mutant aa360–573, including the amino
acid regions of only pep391–410 and pep461–480, reduced
HSP60-binding to 67%.0
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Fig. 2. Eﬀect of selected 20-mer peptides on HSP60-binding to
macrophages. BMM from C57BL/6J mice were incubated in the
absence (autoﬂuorescence) or presence of 500 nM HSP60-Alexa488
(HSP60\) for 45 min on ice. For inhibition studies cells were
preincubated with unlabeled HSP60 or the diﬀerent 20-mer peptides
at the indicated concentrations (30 min), followed by incubation with
HSP60\. The analysis was performed by ﬂow cytometry and binding of
HSP60\ in the absence of inhibitors was set 100%. Error bars represent
mean values + S.D. of three independent experiments. Signiﬁcant
inhibition of binding is indicated as \, P < 0.05.3.3. Diﬀerent HSP60 species do not share binding sites
In a further series of experiments we analyzed the eﬀect of
diﬀerent pro- and eukaryotic HSP60 species on HSP60-binding
to BMM from C57BL/6J mice (Fig. 4). A 10-fold molar excess
of unlabeled human HSP60 strongly competed for binding of
HSP60-Alexa488. Similar degrees of inhibition were observed
with all tested eukaryotic HSP60 species, i.e., hamster HSP60
(72%), mouse HSP60 (69% inhibition), rat HSP60 (72% inhibi-
tion) or H. capsulatum HSP60 (69% inhibition). By contrast,
preincubation of primary macrophages with a 10-fold molar
excess of unlabeled C. pneumoniae HSP60, M. bovis HSP65
or E. coli GroEL did not interfere with the binding of human
HSP60-Alexa488.
3.4. Eﬀect of H. capsulatum HSP60 on human HSP60-binding
to macrophages
Interestingly, preliminary results showed that H. capsulatum
HSP60 also inhibited human HSP60-binding to J774A.1 mac-
rophages. In a more detailed analysis we compared the eﬀect of
H. capsulatum HSP60 and several recombinant H. capsulatum
HSP60-derived fragments corresponding to distinct regions of
the full-length HSP60 molecule, i.e., fragment 1 (aa40–328),
fragment 2 (aa131–394), fragment 3 (aa214–484) and fragmentAutofluorescence
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Fig. 4. Diﬀerential recognition of eukaryotic HSP60 versus procary-
otic HSP60 species by BMM from C57BL/6J mice. Cells were
preincubated for 30 min in the absence (autoﬂuorescence) or presence
of unlabeled HSP60 from diﬀerent species (5 lM), followed by the
addition of 500 nM human HSP60-Alexa488 (HSP60\) for 45 min on
ice. The analysis was performed by ﬂow cytometry and the binding of
HSP60\ alone was set 100%. Error bars represent mean values + S.D.
of three independent experiments. Signiﬁcant inhibition of binding is
indicated as \, P < 0.05.
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Fig. 5. Eﬀect of H. capsulatum HSP60 on HSP60-binding to macro-
phages. (A) BMM from C57BL/6J mice or (B) J774A.1 macrophages
were incubated in the absence (autoﬂuorescence) or presence of
HSP60-Alexa488 (HSP60\) for 45 min on ice. For inhibition studies
cells were preincubated (30 min) with unlabeled human HSP60, H.
capsulatum HSP60 or several H. capsulatum HSP60-derived fragments
(fragment 1: aa40–328, fragment 2: aa131–394, fragment 3: aa214–484,
fragment 4: aa373–590) at the indicated concentrations, followed by
incubation with 500 nM (A) or 350 nM (B) HSP60\. The analysis was
performed by ﬂow cytometry and binding of HSP60\ alone was set
100%.
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C57BL/6J mice and to J774A.1 cells (Fig. 5). Full-length H.
capsulatum HSP60 dose-dependently inhibited human
HSP60-binding to BMM from C57BL/6J mice (22–69% inhibi-
tion) as well as to J774A.1 cells (23–87% inhibition). Preincu-
bation of the two diﬀerent macrophage types with H.
capsulatum HSP60 fragments 1–4 at the same concentration
as HSP60-Alexa488 or at a 10-fold molar excess, resulted in
diﬀerential inhibitory eﬀects. Binding of HSP60-Alexa488 to
BMM from C57BL/6J mice was inhibited by HSP60 fragment
1 (34% and 52% inhibition, respectively), 2 (55% and 71% inhi-
bition, respectively) and 3 (66% and 73% inhibition, respec-
tively). By contrast, only HSP60 fragment 3 competed with
HSP60-binding to J774A.1 macrophages (59% and 69% inhibi-
tion, respectively). HSP60 fragment 4 had no inhibitory eﬀect
on human HSP60-Alexa488-binding to BMM from C57BL/6J
mice and J774A.1 macrophages.4. Discussion
When screening a peptide library to characterize epitope(s)
of the human HSP60 molecule involved in receptor-bindingon primary macrophages, we identiﬁed three peptides corre-
sponding to aa241–260, aa391–410 and aa461–480 of the hu-
man HSP60 sequence. Pep241–260 and pep461–480 were
already inhibitory at a concentration of 5 lM, whereas
pep391–410 competed with HSP60 for binding to BMM from
C57BL/6J mice at a concentration of 125 lM. Our results indi-
cate that eﬃcient contact between HSP60 and macrophages re-
quires the presence of several regions, which contribute to
diﬀerent degrees to HSP60-binding to primary macrophages.
Additional studies with human HSP60 deletion mutants, lack-
ing the N-terminal 137, 243 or 359 amino acids, which inhib-
ited HSP60-binding to BMM from C57BL/6J mice to a
diﬀerent degree, demonstrate that eﬀective HSP60-binding to
primary macrophages depends on the presence of all three re-
gions of the HSP60 molecule. In a 3-D model of the human
HSP60 molecule, deduced from E. coli GroEL, the analog of
mammalian HSP60 (available under swissmodel.expasy.org/
repository), the identiﬁed binding epitope regions can be lo-
cated in the apical (aa241–260), intermediate (aa391–410)
and in the large equatorial (aa461–480) domain of the
HSP60 molecule [21,22]. The contributing amino acids are nei-
ther involved in intramolecular contacts nor in contacts to
adjacent monomers, indicating that the binding epitopes are
accessible to appropriate receptor structures on the surface
of primary macrophages in the monomeric as well as in the
oligomeric state of the HSP60 molecule [21,22].
Interestingly, the identiﬁed amino acid regions involved in
HSP60-binding to primary macrophages are completely diﬀer-
ent to the region previously characterized for binding to
J774A.1 macrophages, i.e., the C-terminal region aa481–500
of the HSP60 molecule [15]. Therefore, we repeated inhibition
experiments with selected peptides on J774A.1 macrophages
and obtained same results as before, i.e., only pep481–500
inhibited HSP60-binding to this macrophage line. These re-
sults were the ﬁrst indication that diﬀerent regions of the
HSP60 molecule and therefore probably diﬀerent receptor
structures are involved in binding to primary macrophages
and to macrophages of the J774A.1 line, respectively.
When analyzing the eﬀect of diﬀerent HSP60 species on hu-
man HSP60-binding to BMM from C57BL/6J mice, we found
that eukaryotic and prokaryotic HSP60 proteins use diﬀerent
binding sites on primary macrophages. All tested eukaryotic
HSP60 species (hamster, mouse, rat and H. capsulatum
HSP60) strongly competed with human HSP60 for binding
to these cells. By contrast, none of the prokaryotic HSP60 spe-
cies (C. pneumoniae, M. bovis and E. coli HSP60) had an eﬀect
on human HSP60-binding. Furthermore, our previous ﬁnding
demonstrating that the binding site for human HSP60 on
mouse macrophages is identical with the receptor for self
HSP60 has been conﬁrmed [14]. Comparative analysis of com-
plete sequences revealed that all investigated mammalian
HSP60 species, i.e., human, hamster, mouse and rat HSP60,
display >95% homology. In contrast, the homology between
mammalian and microbial (C. pneumoniae, M. bovis and
E. coli HSP60) HSP60 species is only around 50%. These ﬁnd-
ings are in agreement with results of sequence alignments of
the three inhibitory human HSP60 peptides with the diﬀerent
microbial HSP60 species (C. pneumoniae, M. bovis and
E. coli HSP60) (Table 1). We found 37–47% homology with
pep241–260, 63–68% with pep391–410 and 32–46% with
pep461–480 in a 13–20 amino acid overlap. Our ﬁndings are
supported by recent reports describing that the recognition
Table 1
Sequence alignments of selected HSP60 fragments of diﬀerent species
HSP60 species Swiss-Prot. Acc. No. Sequence alignment
Human P10809 —241DAYVLLSEKKISSIQSIVPA260—391NERLAKLSDGVAVLKVGGTS410—
Hamster P18687 —241DAYVLLSEKKISSVQSIVPA260—391NERLAKLSDGVAVLKVGGTS410—
Mouse P63038 —241DAYVLLSEKKISSVQSIVPA260—391NERLAKLSDGVAVLKVGGTS410—
Rat P63039 —241DAYVLLSEKKISSVQSIVPA260—391NERLAKLSDGVAVLKVGGTS410—
H. capsulatum P50142 —264KPLIVLSEKKISAVQDIIPA283—404QERLAKLSGGVAVIKVGGAS423—
C. pneumoniae P31681 —217DALILIYDKKISGIKDFLPV236—366QERLAKLSGGVAVIRVGAAT385—
M. bovis P06806 —214DPYILLVSSKVSTVKDLLPL233—363QERLAKLAGGVAVIKAGAAT382—
E. coli P06139 —216SPFILLADKKISNIREMLPV235—365QERVAKLAGGVAVIKVGAAT384—
Human P10809 461QKIGIEIIKRTLKIPAMTIA480—481KNAGVEGSLIVEKIMQSSSE500—
Hamster P18687 461QKIGIEIIKRALKIPAMTIA480—481KNAGVEGSLIVEKILQSSSE500—
Mouse P63038 461QKIGIEIIKRALKIPAMTIA480—481KNAGVEGSLIVEKILQSSSE500—
Rat P63039 461QKIGIEIIKRALKIPAMTIA480—481KNAGVEGSLIVEKILQSSSE500—
H. capsulatum P50142 475QLRRISSLVSAITRPARTIV494—495ENAGLEGSVIVGKLTDEHAS514—
C. pneumoniae P31681 438EAIGTRIILKALTAPLKQIA457—458SNAGKEGAIICQQVLARSAN477—
M. bovis P06806 432EATGANIVKVALEAPLKQIA451—452FNSGLEPGVVAEKVRNLPAG471—
E. coli P06139 435QNVGIKVALRAMEAPLRQIV454—455LNCGEEPSVVANTVKGGDGN474—
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man HSP70 does not share the binding site on innate immune
cells with mycobacterial HSP70, although binding sites reside
on the same membrane protein [23,24]. Because of an impor-
tant role of HSP60 in immunoregulation and the abundance
of HSP60 proteins in both, mammalian and microbial cells,
it may be essential for innate immune cells to distinguish
HSP60 by their endogenous or infectious origin.
Interestingly, H. capsulatum HSP60 inhibited human
HSP60-binding to primary macrophages as well as to macro-
phages of the line J774A.1 cells, although H. capsulatum
HSP60 displays 50% sequence homology to microbial
HSP60 species and 60% homology to mammalian HSP60.
This could be explained by the results of sequence alignments
of the selected epitope regions of human HSP60 involved in
binding to primary cells as well as to J774A.1 macrophages.
The sequence homology between the four amino acid regions
aa241–260, aa391–410, aa461–480 and aa481–500 of human
HSP60 and H. capsulatum HSP60 was 50–84% with a 10–19
amino acid overlap. Detailed analysis using several fragments
ofH. capsulatumHSP60 showed that HSP60 fragment 1, 2 and
3 strongly inhibited human HSP60-binding to BMM from
C57BL/6J mice. By contrast, only H. capsulatum HSP60 frag-
ment 3 competed with human HSP60 for binding to J774A.1
macrophages. These results support our previous assumption
that diﬀerent regions of the HSP60 molecule and diﬀerent sur-
face receptors are involved in the interaction with BMM from
C57BL/6J mice and J774A.1 macrophages. This hypothesis is
further strongly supported by the ﬁnding, that hamster
HSP60 inhibited binding of human HSP60 to BMM from
C57BL/6J mice, whereas it had no eﬀect on HSP60-binding
to J774A.1 macrophages [14]. It is probable that J774A.1 cells,
a tumor-derived macrophage line, express diﬀerent receptor
structures compared to primary macrophages like BMM.
For instance, the mannose receptor has been found to be ex-
pressed only in primary macrophages, but not in established
macrophage lines like J774A.1 [25]. Furthermore, diﬀerent
receptors in dependence on the cell type have been described
to be involved in interaction with HSP [26–29]. CD91,
CD40, LOX-1 and CD94 have been described as binding
receptors for HSP70 on diﬀerent immune cells [24,26–28].
However, ﬁndings obtained by investigating primary cells are
more reﬂecting the in vivo situation.HSP60 has been identiﬁed as immunodominant target in
inﬂammatory diseases like arthritis, type 1 diabetes and athero-
sclerosis [3–6]. The analysis of immune responses to HSP60 in
experimental models and in patients with organ-speciﬁc inﬂam-
matory diseases indicate that HSP60 has the capacity to induce
regulatory T-cell responses [5,7,30–33]. In the pathogenesis of
these diseases the interaction of HSP60 with cells of the innate
immune system, such as macrophages, is the initial event lead-
ing to the activation of organ-speciﬁc immune responses by the
innate as well as the adaptive immune system [7]. Therefore, the
identiﬁcation of epitope regions of the HSP60 molecule in-
volved in the interaction with cell surface structures on innate
immune cells, which in turn may lead to the activation of these
cells, provides important informations for the understanding of
the immunoregulatory potential of HSP60.
Acknowledgements:We are grateful to Dr. D. Elias (Peptor Inc., Reho-
vot, Israel) for a generous gift of human recombinant HSP60. We
thank Dr. T. Miethke from the Institute for Medical Microbiology,
Immunology and Hygiene, Technical University of Munich (Munich,
Germany) for providing recombinant C. pneumoniae HSP60. This
work was supported by grants from the Deutsche Forschungsgemeins-
chaft, by the European Commission through the Concerted action
‘‘Heat Shock Proteins in Inﬂammatory Diseases’’ (Project BMH4-
CT98-3935) and through the RTD project ‘‘HSP for Therapy’’ (Project
QLG1-CT-2002-01287), by Peptor Inc., by the Bundesminister fu¨r
Gesundheit und Soziale Sicherung, and by the Minister fu¨r Bildung
und Forschung des Landes Nordrhein-Westfalen.References
[1] Bukau, B., Deuerling, E., Pfund, C. and Craig, E.A. (2000)
Getting newly synthesized proteins into shape. Cell 101, 119–122.
[2] Hartl, F.U. and Hayer-Hartl, M. (2002) Protein folding –
molecular chaperones in the cytosol: from nascent chain to folded
protein. Science 295, 1852–1858.
[3] Feige, U. and Cohen, I.R. (1991) The 65-kDa heat-shock protein
in the pathogenesis of, prevention and therapy of autoimmune
arthritis and diabetes mellitus in rats and mice. Springer Semin.
Immunopathol. 13, 99–113.
[4] Kamphuis, S., Kuis, W., de Jager, W., Teklenburg, G., Massa,
M., Gordon, G., Boerhof, M., Rijkers, G.T., Uiterwaal, C.S.,
Otten, H.G., Sette, A., Albani, S. and Prakken, B. (2005)
Tolerogenic immune responses to novel T-cell epitopes from
heat-shock protein 60 in juvenile idiopathic arthritis. Lancet 366,
50–56.
[5] Abulaﬁa-Lapid, R., Elias, D., Raz, I., Keren-Zur, Y., Atlan, H.
and Cohen, I.R. (1999) T cell proliferative responses of type 1
120 C. Habich et al. / FEBS Letters 580 (2006) 115–120diabetes patients and healthy individuals to human hsp60 and its
peptides. J. Autoimmun. 12, 121–129.
[6] Xu, Q., Schett, G., Perschinka, H., Mayr, M., Egger, G.,
Oberhollenzer, F., Willeit, J., Kiechl, S. and Wick, G. (2000)
Serum soluble heat shock protein 60 is elevated in subjects
with atherosclerosis in a general population. Circulation 102,
14–20.
[7] van Eden, W., van der Zee, R. and Prakken, B. (2005) Heat-shock
proteins induce T-cell regulation of chronic inﬂammation. Nat.
Rev. Immunol. 5, 318–330.
[8] Chen, W., Syldath, U., Bellmann, K., Burkart, V. and Kolb, H.
(1999) Human 60-kDa heat-shock protein: a danger signal to the
innate immune system. J. Immunol. 162, 3212–3219.
[9] Kol, A., Bourcier, T., Lichtman, A.H. and Libby, P. (1999)
Chlamydial and human heat shock protein 60s activate human
vascular endothelium, smooth muscle cells, and macrophages. J.
Clin. Invest. 103, 571–577.
[10] Vabulas, R.M., Ahmad-Nejad, P., da Costa, C., Miethke, T.,
Kirschning, C.J., Ha¨cker, H. and Wagner, H. (2001) Endocytosed
HSP60s use Toll-like receptor 2 (TLR2) and TLR4 to activate the
Toll/interleukin-1 receptor signaling pathway in innate immune
cells. J. Biol. Chem. 276, 31332–31339.
[11] Flohe´, S.B., Bru¨ggemann, J., Lendemans, S., Nikulina, M.,
Meierhoﬀ, G., Flohe´, S. and Kolb, H. (2003) Human heat shock
protein 60 induces maturation of dendritic cells versus a Th1-
promoting phenotype. J. Immunol. 170, 2340–2348.
[12] Habich, C., Baumgart, K., Kolb, H. and Burkart, V. (2002) The
receptor for heat shock protein 60 on macrophages is saturable,
speciﬁc, and distinct from receptors for other heat shock proteins.
J. Immunol. 168, 569–576.
[13] Ohashi, K., Burkart, V., Flohe´, S. and Kolb, H. (2000) Heat
shock protein 60 is a putative endogenous ligand of the Toll-like
receptor-4 complex. J. Immunol. 164, 558–561.
[14] Habich, C., Kempe, K., van der Zee, R., Burkart, V. and Kolb, H.
(2003) Diﬀerent heat shock protein 60 species share pro-inﬂam-
matory activity but not binding sites on macrophages. FEBS Lett.
533, 105–109.
[15] Habich, C., Kempe, K., Burkart, V., van der Zee, R., Lillicrap,
M., Gaston, H. and Kolb, H. (2004) Identiﬁcation of the heat
shock protein 60 epitope involved in receptor binding on
macrophages. FEBS Lett. 568, 65–69.
[16] Habich, C., Kempe, K., van der Zee, R., Ru¨menapf, R.,
Akiyama, H., Kolb, H. and Burkart, V. (2005) Heat shock
protein 60: speciﬁc binding of lipopolysaccharide. J. Immunol.
174, 1298–1305.
[17] Jindal, S., Dudani, A.K., Singh, B., Harley, C.B. and Gupta, R.S.
(1989) Primary structure of a human mitochondrial protein
homologous to the bacterial and plant chaperonins and to the 65-
kilodalton mycobacterial antigen. Mol. Cell. Biol. 9, 2279–2283.
[18] Gomez, F.J., Gomez, A.M. and Deepe, G.S. (1991) Protective
eﬃcacy of a 62-kilodalton antigen, HIS-62, from the cell wall and
cell membrane of Histoplasma capsulatum yeast cells. Infect.
Immun. 59, 4459–4464.
[19] Gomez, F.J., Allendoerfer, R. and Deepe, G.S. (1995) Vaccina-
tion with recombinant heat shock protein 60 from Histoplasma
capsulatum protects mice against pulmonary histoplasmosis.
Infect. Immun. 63, 2587–2595.[20] Deepe, G.S., Gibbons, J.R., Brunner, G.D. and Gomez, F.J.
(1996) A protective domain of heat-shock protein 60 from
Histoplasma capsulatum. J. Infect. Dis. 174, 828–834.
[21] Braig, K., Otwinowski, Z., Hegde, R., Boisvert, D.C., Joachi-
miak, A., Horwich, A.L. and Sigler, P.B. (1994) The crystal
structure of the bacterial chaperonin GroEL at 2.8 A˚. Nature 371,
578–586.
[22] Brocchieri, L. and Karlin, S. (2000) Conservation among HSP60
sequences in relation to structure, function, and evolution. Protein
Sci. 9, 476–486.
[23] Wang, Y., Kelly, C.G., Karttunen, J.T., Whittall, T., Lehner,
P.J., Duncan, L., MacAry, P., Younson, J.S., Singh, M.,
Oehlmann, W., Cheng, G., Bergmeier, L. and Lehner, T.
(2001) CD40 is a cellular receptor mediating mycobacterial
heat shock protein 70 stimulation of CC-mediating mycobac-
terial heat shock protein 70 stimulation of CC-chemokines.
Immunity 15, 971–983.
[24] Becker, T., Hartl, F.U. and Wieland, F. (2002) CD40, an
extracellular receptor for binding and uptake of HSP70-peptide
complexes. J. Cell. Biol. 158, 1277–1285.
[25] Diment, S., Leech, M.S. and Stahl, P.D. (1987) Generation of
macrophage variants with 5-azacytidine: selection for mannose
receptor expression. J. Leukoc. Biol. 42, 485–490.
[26] Basu, S., Binder, R.J., Ramalingam, T. and Srivastava, P.K.
(2001) CD91 is a common receptor for heat shock proteins gp96,
hsp90, hsp70, and calreticulin. Immunity 14, 303–313.
[27] Delneste, Y., Magistrelli, G., Gauchat, J., Haeuw, J., Aubry, J.,
Nakamura, K., Kawakami-Honda, N., Goetsch, L., Sawamura,
T., Bonnefoy, J. and Jeannin, P. (2002) Involvement of LOX-1 in
dendritic cell-mediated antigen cross-presentation. Immunity 17,
353–362.
[28] Gross, K., Hansch, D., Gastpar, R. and Multhoﬀ, G. (2003)
Interaction of heat shock protein 70 peptide with NK cells
involves the NK receptor CD94. Biol. Chem. 384, 267–279.
[29] The´riault, J.R., Mambula, S.S., Sawamura, T., Stevenson, M.A.
and Calderwood, S.K. (2005) Extracellular HSP70 binding to
surface receptors present on antigen presenting cells and endo-
thelial/epithelial cells. FEBS Lett. 579, 1951–1960.
[30] de Kleer, I.M., Kamphuis, S.M., Rijkers, G.T., Scholtens, L.,
Gordon, G., de Jager, W., Hafner, R., van der Zee, R., van Eden,
W., Kuis, W. and Prakken, B.J. (2003) The spontaneous
remission of juvenile idiopathic arthritis is characterized by
CD30+ T cells directed to human heat-shock protein 60 capable
of producing the regulatory cytokine interleukin-10. Arthritis
Rheum. 48, 2001–2010.
[31] de Kleer, I.M., Wedderburn, L.R., Taams, L.S., Patel, A.,
Varsani, H., Klein, M., de Jager, W., Pugayung, G., Giannoni,
F., Rijkers, G.T., Albani, S., Kuis, W. and Prakken, B. (2004)
CD4+CD25 bright regulatory T cells actively regulate inﬂamma-
tion in the joints of patients with the remitting form of juvenile
idiopathic arthritis. J. Immunol. 172, 6435–6443.
[32] Cohen, I.R. (2002) Peptide therapy for type 1 diabetes: the
immunological homunculus and the rationale for vaccination.
Diabetolgia 45, 1468–1474.
[33] Wick, G., Knoﬂach, M. and Xu, Q. (2004) Autoimmune and
inﬂammatory mechanisms in atherosclerosis. Annu. Rev. Immu-
nol. 22, 361–403.
